Literature DB >> 20805359

Cortactin modulates RhoA activation and expression of Cip/Kip cyclin-dependent kinase inhibitors to promote cell cycle progression in 11q13-amplified head and neck squamous cell carcinoma cells.

David R Croucher1, Danny Rickwood, Carole M Tactacan, Elizabeth A Musgrove, Roger J Daly.   

Abstract

The cortactin oncoprotein is frequently overexpressed in head and neck squamous cell carcinoma (HNSCC), often due to amplification of the encoding gene (CTTN). While cortactin overexpression enhances invasive potential, recent research indicates that it also promotes cell proliferation, but how cortactin regulates the cell cycle machinery is unclear. In this article we report that stable short hairpin RNA-mediated cortactin knockdown in the 11q13-amplified cell line FaDu led to increased expression of the Cip/Kip cyclin-dependent kinase inhibitors (CDKIs) p21(WAF1/Cip1), p27(Kip1), and p57(Kip2) and inhibition of S-phase entry. These effects were associated with increased binding of p21(WAF1/Cip1) and p27(Kip1) to cyclin D1- and E1-containing complexes and decreased retinoblastoma protein phosphorylation. Cortactin regulated expression of p21(WAF1/Cip1) and p27(Kip1) at the transcriptional and posttranscriptional levels, respectively. The direct roles of p21(WAF1/Cip1), p27(Kip1), and p57(Kip2) downstream of cortactin were confirmed by the transient knockdown of each CDKI by specific small interfering RNAs, which led to partial rescue of cell cycle progression. Interestingly, FaDu cells with reduced cortactin levels also exhibited a significant diminution in RhoA expression and activity, together with decreased expression of Skp2, a critical component of the SCF ubiquitin ligase that targets p27(Kip1) and p57(Kip2) for degradation. Transient knockdown of RhoA in FaDu cells decreased expression of Skp2, enhanced the level of Cip/Kip CDKIs, and attenuated S-phase entry. These findings identify a novel mechanism for regulation of proliferation in 11q13-amplified HNSCC cells, in which overexpressed cortactin acts via RhoA to decrease expression of Cip/Kip CDKIs, and highlight Skp2 as a downstream effector for RhoA in this process.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20805359      PMCID: PMC2953065          DOI: 10.1128/MCB.00249-10

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  57 in total

1.  p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27.

Authors:  L M Tsvetkov; K H Yeh; S J Lee; H Sun; H Zhang
Journal:  Curr Biol       Date:  1999-06-17       Impact factor: 10.834

2.  Transformation mediated by RhoA requires activity of ROCK kinases.

Authors:  E Sahai; T Ishizaki; S Narumiya; R Treisman
Journal:  Curr Biol       Date:  1999-02-11       Impact factor: 10.834

3.  Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase.

Authors:  Takumi Kamura; Taichi Hara; Masaki Matsumoto; Noriko Ishida; Fumihiko Okumura; Shigetsugu Hatakeyama; Minoru Yoshida; Keiko Nakayama; Keiichi I Nakayama
Journal:  Nat Cell Biol       Date:  2004-11-07       Impact factor: 28.824

4.  Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1.

Authors:  M F Olson; H F Paterson; C J Marshall
Journal:  Nature       Date:  1998-07-16       Impact factor: 49.962

5.  New functional activities for the p21 family of CDK inhibitors.

Authors:  J LaBaer; M D Garrett; L F Stevenson; J M Slingerland; C Sandhu; H S Chou; A Fattaey; E Harlow
Journal:  Genes Dev       Date:  1997-04-01       Impact factor: 11.361

6.  An invasion-related complex of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular matrix degradation.

Authors:  E T Bowden; M Barth; D Thomas; R I Glazer; S C Mueller
Journal:  Oncogene       Date:  1999-08-05       Impact factor: 9.867

7.  EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer.

Authors:  R Hui; D H Campbell; C S Lee; K McCaul; D J Horsfall; E A Musgrove; R J Daly; R Seshadri; R L Sutherland
Journal:  Oncogene       Date:  1997-09-25       Impact factor: 9.867

8.  The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts.

Authors:  M Cheng; P Olivier; J A Diehl; M Fero; M F Roussel; J M Roberts; C J Sherr
Journal:  EMBO J       Date:  1999-03-15       Impact factor: 11.598

9.  Overexpression of EMS1/cortactin in NIH3T3 fibroblasts causes increased cell motility and invasion in vitro.

Authors:  A S Patel; G L Schechter; W J Wasilenko; K D Somers
Journal:  Oncogene       Date:  1998-06-25       Impact factor: 9.867

10.  The role of tyrosine phosphorylation of cortactin in the locomotion of endothelial cells.

Authors:  C Huang; J Liu; C C Haudenschild; X Zhan
Journal:  J Biol Chem       Date:  1998-10-02       Impact factor: 5.157

View more
  11 in total

Review 1.  Cortactin in cell migration and cancer at a glance.

Authors:  Stacey M MacGrath; Anthony J Koleske
Journal:  J Cell Sci       Date:  2012-04-01       Impact factor: 5.285

2.  Homo- and Heterotypic Association Regulates Signaling by the SgK269/PEAK1 and SgK223 Pseudokinases.

Authors:  Ling Liu; Yu Wei Phua; Rachel S Lee; Xiuquan Ma; Yiping Jenkins; Karel Novy; Emily S Humphrey; Howard Chan; Robert Shearer; Poh Chee Ong; Weiwen Dai; Darren N Saunders; Isabelle S Lucet; Roger J Daly
Journal:  J Biol Chem       Date:  2016-08-16       Impact factor: 5.157

Review 3.  Cortactin: a multifunctional regulator of cellular invasiveness.

Authors:  Kellye C Kirkbride; Bong Hwan Sung; Seema Sinha; Alissa M Weaver
Journal:  Cell Adh Migr       Date:  2011-03-01       Impact factor: 3.405

4.  VEGF-A/NRP1 stimulates GIPC1 and Syx complex formation to promote RhoA activation and proliferation in skin cancer cells.

Authors:  Ayumi Yoshida; Akio Shimizu; Hirotsugu Asano; Tetsuya Kadonosono; Shinae Kizaka Kondoh; Elena Geretti; Akiko Mammoto; Michael Klagsbrun; Misuzu Kurokawa Seo
Journal:  Biol Open       Date:  2015-07-24       Impact factor: 2.422

5.  Loss of cortactin causes endothelial barrier dysfunction via disturbed adrenomedullin secretion and actomyosin contractility.

Authors:  Alexander García Ponce; Alí F Citalán Madrid; Hilda Vargas Robles; Sandra Chánez Paredes; Porfirio Nava; Abigail Betanzos; Alexander Zarbock; Klemens Rottner; Dietmar Vestweber; Michael Schnoor
Journal:  Sci Rep       Date:  2016-06-30       Impact factor: 4.379

6.  The HBx-CTTN interaction promotes cell proliferation and migration of hepatocellular carcinoma via CREB1.

Authors:  Yajun Li; Yongming Fu; Xingwang Hu; Lunquan Sun; Daolin Tang; Ning Li; Fang Peng; Xue-Gong Fan
Journal:  Cell Death Dis       Date:  2019-05-28       Impact factor: 8.469

7.  Profiling the expression of pro-metastatic genes in association with the clinicopathological features of primary breast cancer.

Authors:  Seyed-Mohammad Mazloomi; Mitra Foroutan-Ghaznavi; Vahid Montazeri; Gholamreza Tavoosidana; Ashraf Fakhrjou; Hojjatollah Nozad-Charoudeh; Saeed Pirouzpanah
Journal:  Cancer Cell Int       Date:  2021-01-06       Impact factor: 5.722

8.  Crumbs3 is expressed in oral squamous cell carcinomas and promotes cell migration and proliferation by affecting RhoA activity.

Authors:  Yusuke Yokoyama; Hidekazu Iioka; Arata Horii; Eisaku Kondo
Journal:  Oncol Lett       Date:  2022-04-13       Impact factor: 3.111

9.  The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling.

Authors:  Carole M Tactacan; Yu Wei Phua; Ling Liu; Luxi Zhang; Emily S Humphrey; Mark Cowley; Mark Pinese; Andrew V Biankin; Roger J Daly
Journal:  Mol Cancer       Date:  2015-07-29       Impact factor: 27.401

10.  Novel role of cortactin in G protein-coupled receptor agonist-induced nuclear export and degradation of p21Cip1.

Authors:  Jagadeesh Janjanam; Gadiparthi N Rao
Journal:  Sci Rep       Date:  2016-07-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.